Cereus savings—successful use of dalbavancin in an immunocompromised patient with Bacillus cereus bacteremia
- 1Department of Pharmacy, SSM Health DePaul Hospital, Bridgeton, Missouri, USA
- 2Division of Infectious Diseases, Allergy and Immunology, SSM Health Saint Louis University Hospital, St. Louis, Missouri, USA
- 3Department of Pathology, SSM Health, Saint Louis University, St. Louis, Missouri, USA
Abstract
Background: Dalbavancin’s pharmacokinetics (long half-life, high tissue penetration, once-weekly dosing) make it an attractive alternative for patients with barriers to outpatient parenteral antimicrobial therapy or at risk for line-related complications. In this case, we used dalbavancin to promote timely discharge for an immunocompromised patient who experienced Bacillus cereus bacteremia due to a peripherally inserted central catheter (PICC) line-associated infection. Although B. cereus is known to cause line-related infections, we present a novel clinical case highlighting the successful use of dalbavancin in an immunocompromised patient with B. cereus bacteremia, and this approach also facilitated earlier discharge.
Case Summary: A 58-year-old woman with invasive ductal breast cancer on chemotherapy (docetaxel, carboplatin, trastuzumab, pertuzumab), mechanical aortic valve replacement, and other comorbidities presented with febrile neutropenia 2 weeks after her fifth chemotherapy cycle. A month prior, she had completed vancomycin for a suspected port infection. Admission laboratory values revealed pancytopenia (white blood cell count [WBC] 1.7 × 10⁹/L, absolute neutrophil count [ANC] 0.53 × 10⁹/L, hemoglobin 7.8 g/dL, and platelets 51 × 10⁹/L). Both sets of blood cultures obtained prior to empiric vancomycin grew B. cereus, with positive cultures throughout day 3 despite treatment. A transthoracic and transesophageal echocardiography excluded endocarditis. The PICC line was removed on day 2; blood cultures cleared by day 5, and neutropenia resolved on day 7. Given two prior catheter-related infections and logistical challenges with weekend discharge planning, the patient received a single 1,500 mg dose of intravenous dalbavancin rather than receiving a new line and continuing prolonged intravenous therapy. This facilitated discharge 4 days earlier than anticipated. At 2.5-week follow-up and visits at 30, 60, and 90 days, the patient remained clinically well without recurrence of infection.
Conclusion: This case highlights successful off-label use of dalbavancin in a complex case, suggesting that its use in such cases warrants further studies, especially when standard regimens can be logistically challenging.
Related
- Bacillus clausii-associated bacteremia following probiotic use: A report of two cases and a review of the literature.
- Persistent Bacillus cereus bacteremia in a patient with systemic sclerosis-associated intestinal pseudo-obstruction: A case report.
- In vitro susceptibility of Cutibacterium acnes to dalbavancin: comparison between gradient test and the agar dilution reference method.
- Xanthogranulomatous Pyelonephritis in a Horseshoe Kidney: Effective Conservative Therapy in an Immunocompromised Patient
- Rare Fatal Event of Multidrug-resistant Shigella Septicemia and Cryptococcal Meningitis in an Immunocompromised Host
BibTeX
@article{eaton2026cereus,
title = {{Cereus savings—successful use of dalbavancin in an immunocompromised patient with Bacillus cereus bacteremia}},
author = {Daisy L. Eaton and Matthew Stack and Robin Chamberland and Hunter O. Rondeau},
journal = {ASM case reports},
year = {2026},
month = sep,
doi = {10.1128/asmcr.00024-26},
url = {https://europepmc.org/article/PMC/PMC13729743},
note = {CC BY},
}
RIS
TY - JOUR
TI - Cereus savings—successful use of dalbavancin in an immunocompromised patient with Bacillus cereus bacteremia
AU - Daisy L. Eaton
AU - Matthew Stack
AU - Robin Chamberland
AU - Hunter O. Rondeau
PY - 2026
DA - 2026/09/09
JO - ASM case reports
DO - 10.1128/asmcr.00024-26
UR - https://europepmc.org/article/PMC/PMC13729743
AB - Background: Dalbavancin’s pharmacokinetics (long half-life, high tissue penetration, once-weekly dosing) make it an attractive alternative for patients with barriers to outpatient parenteral antimicrobial therapy or at risk for line-related complications. In this case, we used dalbavancin to promote timely discharge for an immunocompromised patient who experienced Bacillus cereus bacteremia due to a peripherally inserted central catheter (PICC) line-associated infection. Although B. cereus is known to cause line-related infections, we present a novel clinical case highlighting the successful use of dalbavancin in an immunocompromised patient with B. cereus bacteremia, and this approach also facilitated earlier discharge. Case Summary: A 58-year-old woman with invasive ductal breast cancer on chemotherapy (docetaxel, carboplatin, trastuzumab, pertuzumab), mechanical aortic valve replacement, and other comorbidities presented with febrile neutropenia 2 weeks after her fifth chemotherapy cycle. A month prior, she had completed vancomycin for a suspected port infection. Admission laboratory values revealed pancytopenia (white blood cell count [WBC] 1.7 × 10⁹/L, absolute neutrophil count [ANC] 0.53 × 10⁹/L, hemoglobin 7.8 g/dL, and platelets 51 × 10⁹/L). Both sets of blood cultures obtained prior to empiric vancomycin grew B. cereus, with positive cultures throughout day 3 despite treatment. A transthoracic and transesophageal echocardiography excluded endocarditis. The PICC line was removed on day 2; blood cultures cleared by day 5, and neutropenia resolved on day 7. Given two prior catheter-related infections and logistical challenges with weekend discharge planning, the patient received a single 1,500 mg dose of intravenous dalbavancin rather than receiving a new line and continuing prolonged intravenous therapy. This facilitated discharge 4 days earlier than anticipated. At 2.5-week follow-up and visits at 30, 60, and 90 days, the patient remained clinically well without recurrence of infection. Conclusion: This case highlights successful off-label use of dalbavancin in a complex case, suggesting that its use in such cases warrants further studies, especially when standard regimens can be logistically challenging.
SN - 2996-2684
ER -